(5/11, Burba) reports researchers found “lymph node status is a predictor of survival in patients with vulvar melanoma [VuM] and vaginal melanoma [VaM].” The study’s authors said, “Lymph node status and mitotic rate are the most important predictors for disease-specific survival. Lymph node status should be assessed in all applicable patients with VuM and VaM. […]
(5/8) the FDA expanded the approval of AstraZeneca and Merck & Co.’s PARP inhibitor Lynparza (olaparib) “to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.” The agency’s expanded approval “applies to use of” the combination treatment “by women who […]
According to study results being presented at the virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, the preliminary results gathered from this clinical trial showed strong activity of WEE1-directed therapy in uterine serous carcinoma (USC). The drug targets the WEE1 protein, which regulates the G2/M checkpoint.“Adavosertib demonstrated remarkable activity […]